Compare Stocks → A new way to collect income from stocks (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DFFNNASDAQ:GEMPNASDAQ:IMRNNASDAQ:PHIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsGEMPGemphire Therapeutics$3.40-3.7%$4.97$0.24▼$1.49$50.57M2.82127,174 shs12,946 shsIMRNImmuron$2.41+0.4%$5.04$1.92▼$28.99$13.74M1.4326,499 shs1,301 shsPHIOPhio Pharmaceuticals$0.64-1.5%$0.79$0.50▼$12.27$2.94M1.44285,722 shs39,722 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%-31.46%GEMPGemphire Therapeutics-2.22%-11.08%-23.26%+3.22%+325.30%IMRNImmuron-7.34%-12.89%-16.38%+26.98%+21.21%PHIOPhio Pharmaceuticals+0.49%-3.79%-31.06%+2.17%-89.24%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.9915 of 5 stars3.55.00.00.01.92.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00523.54% UpsideCurrent Analyst RatingsLatest PHIO, IMRN, GEMP, and DFFN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AIMRNImmuron$1.22M11.26N/AN/A$2.32 per share1.04PHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDFFNDiffusion Pharmaceuticals-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AIMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/APHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDFFNDiffusion PharmaceuticalsN/A10.7110.71GEMPGemphire TherapeuticsN/A0.670.67IMRNImmuronN/A8.527.79PHIOPhio PharmaceuticalsN/A5.705.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDFFNDiffusion Pharmaceuticals9.95%GEMPGemphire Therapeutics17.53%IMRNImmuron0.12%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipDFFNDiffusion Pharmaceuticals1.80%GEMPGemphire Therapeutics22.70%IMRNImmuron7.01%PHIOPhio Pharmaceuticals0.77%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionablePHIO, IMRN, GEMP, and DFFN HeadlinesSourceHeadlinePhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)globenewswire.com - April 16 at 7:30 AMPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)globenewswire.com - April 11 at 7:30 AMNational Spotlight Features Phio’s Innovative RNAi Technology Platformfinance.yahoo.com - April 3 at 10:33 AMNational Spotlight Features Phio's Innovative RNAi Technology Platformglobenewswire.com - April 3 at 7:30 AMPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Updateglobenewswire.com - April 2 at 7:30 AMPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - March 21 at 7:52 AMPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Researchglobenewswire.com - March 13 at 2:00 PMPhio Pharmaceuticals Corp PHIOmorningstar.com - March 10 at 7:10 AMAnalysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)markets.businessinsider.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disordersfinance.yahoo.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disordersglobenewswire.com - March 6 at 10:30 AMChallenges and Opportunities for Key Players in the Hypopigmentation Disorder Product Marketopprairie.com - February 23 at 1:35 PMDry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030uk.finance.yahoo.com - February 14 at 10:33 AMAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)markets.businessinsider.com - February 6 at 1:30 PMPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - January 31 at 8:14 AMPhio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of Listingcbonds.com - January 28 at 12:19 PMRecent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)knoxdaily.com - January 1 at 1:39 PMPhio Pharmaceuticals files to sell 4.42M shares of common stock for holdersmsn.com - December 19 at 9:00 PMWhy Phio Pharmaceuticals Stock Is Nosedivingmsn.com - December 7 at 5:55 PMPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceedsfinance.yahoo.com - December 7 at 12:54 PMPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 10 at 1:31 PMPhio Pharmaceuticals enrolls first patient in clinical trialwbjournal.com - November 10 at 1:31 PMPhio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29msn.com - November 10 at 1:31 PMPhio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 9 at 8:25 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDiffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.